Eun Yang
Stock Analyst at Jefferies
(0.53)
# 4,233
Out of 5,241 analysts
31
Total ratings
35.29%
Success rate
-23.53%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $28.30 | +48.41% | 1 | Nov 5, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $566.80 | -23.78% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $5.19 | +54.29% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $56 → $12 | $14.19 | -15.43% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $66.00 | -50.00% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.22 | +2,195.08% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $40.17 | -32.79% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.90 | +268.42% | 1 | Feb 10, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $2.70 | +825.93% | 1 | Nov 14, 2022 | |
| NCNA NuCana | Maintains: Buy | $105,000 → $15,000 | $1.98 | +757,475.76% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.92 | +1,205.48% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $39.70 | -11.84% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $330.75 | -33.48% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $190.56 | +62.68% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $130.50 | -38.70% | 3 | Jul 11, 2017 |
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $28.30
Upside: +48.41%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $566.80
Upside: -23.78%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $5.19
Upside: +54.29%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $56 → $12
Current: $14.19
Upside: -15.43%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $66.00
Upside: -50.00%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.22
Upside: +2,195.08%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $40.17
Upside: -32.79%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.90
Upside: +268.42%
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $2.70
Upside: +825.93%
NuCana
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $1.98
Upside: +757,475.76%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.92
Upside: +1,205.48%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $39.70
Upside: -11.84%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $330.75
Upside: -33.48%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $190.56
Upside: +62.68%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $130.50
Upside: -38.70%